Virax Biolabs Group Limited Ordinary Shares (VRAX)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses, honest accounting, and a margin of safety. Virax Biolabs, at the 2026-10-13 close of $1.74, has a $1.1 million market cap and 26 employees. It is developing ViraxImmune, a T-cell immune profiling platform for post-acute infection syndromes. That is a scientifically interesting niche, but I see no evidence of a moat: revenue growth and profit growth are both N/A, and the Lynch category is none because there are only zero years of filed annual results, not the three needed. Financial health is poor. The Piotroski F-Score is 1/9, and the Altman Z-Score is -3.41, both pointing to distress. Return on equity is -78.65% and return on capital employed is -54.23%, so capital is being consumed, not compounded. Debt is low at D/E 0.06, which helps, but low debt does not make a money-losing diagnostic platform safe. On valuation, P/B is 0.13, so the shares trade far below stated book value. Graham might glance at that, but he would ask whether those assets are realizable and why the business is not earning. The negative P/E of -0.14 tells me there are no positive earnings to value. The 52-week range of $0.10 to $13.19 shows extreme speculation, not stability, and beta is 1.35. In sum, this is a speculative medical hypothesis, not a Buffett-style compounder. I would want a clear path to revenue, a multi-year record, and a balance sheet that survives years of losses before calling it investment grade.

In plain English: Virax Biolabs is a very small biotech company working on tests that study immune-system T cells for illnesses linked to viral infections, such as long COVID. The business looks weak: it is losing money, has no shown revenue growth, and has a very short reporting history. The stock price may look low compared with its accounting value, but the numbers point to high risk rather than a clear bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer